Christian Kanstrup, Chief Executive Officer at Evaxion, commented: “We have made significant progress in our business and our financing strategies in recent months, notably the successful closing of our bridge financing round towards the end of 2023 and a subsequent public offering in early February 2024. We are very pleased with the MSD GHI participation in both financing rounds, following which we now have cash at hand into Q1 2025.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EVAX:
- Evaxion Biotech Reveals AI-Driven Vaccine Innovations
- Evaxion Biotech hosts R&D day, unveils potential of AI-Immunology platform
- Evaxion Hosts R&D Day and Unveils the Broad Potential of Its AI-Immunology™ Platform
- Evaxion to Host R&D Day on March 19, 2024, Highlighting its Latest Technology Innovations
- Evaxion announces completion of initial phases of collaboration with MSD
